Lanzamiento Enero 2027

Estudio2017

Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition

Berman MH, Halper JP, Nichols TW, Jarrett H, Lundy A, Huang JH

Journal of neurology and neuroscience · 113 citas

Cómo se estudió

Diseño
Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
Estudiado en
Personas
Resultado principal
Marcadores de salud y funcionamiento

Quién lo pagó

Financiación
Financiación independiente
Gobierno
National Institutes of Health
Gobierno
National Institute of Neurological Disorders and Stroke
Gobierno
NINDS NIH HHS
Subvenciones
National Institute of Neurological Disorders and Stroke (R01-NS-067435); National Institutes of Health (R01 NS067435)

Según 3 financiadores declarados.

Publicación

Publicado
2017-01-01 · J Neurol Neurosci · vol. 08 · número 01
Citado
172 citas · más que el 98% de estudios similares · 7.7× el promedio de su campo
Impacto
Entre el 10 % más citado de su campo
Referencias
20 trabajos
Acceso
Lectura gratuita
Áreas de investigación
Laser Applications in Dentistry and Medicine · Photoreceptor and optogenetics research · Planarian Biology and Electrostimulation
Palabras clave
Dementia, Medicine, Clinical trial, Placebo, Cognitive decline, Neuroscience, Disease, Internal medicine, Psychology, Pathology

6 autores

  • Marvin H. Berman🇺🇸Quietmind Foundation
  • James P. Halper🇺🇸Quietmind Foundation
  • Trent W Nichols🇺🇸 · autor de correspondenciaQuietmind Foundation
  • Hugh Jarrett🇺🇸Quietmind Foundation
  • Alan Lundy🇺🇸Quietmind Foundation
  • Jason Haitao Huang🇺🇸 · autor de correspondenciaBaylor Scott & White Medical Center - Temple; Quietmind Foundation

Resumen

El texto original del estudio, en el idioma en que se publicó.

Alzheimer's disease (AD) is a common, chronic expensive debilitating neurodegenerative disease with no current treatments to prevent the physical deterioration of the brain and the consequent cognitive deficits. The current pathophysiology of Alzheimer's disease is the accumulation of neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein and amyloid-beta (Aβ) plaques. Antibody therapy of Tau and Amyloid beta, vaccines and other methods to decrease Tau and or Amyloid have not been successful after considerable pharmaceutical and biotech efforts. For example, Eli Lilly announced a major change to its closely watched clinical trial for the Alzheimer's drug solanezumab which failed to reach statistical significance. Recently, a report on animal models using photomodulation with near infrared light to treat AD pathology in K369I tau transgenic model (K3) l engineered to develop neurofibrillary tangles, and the APPs/PSEN1dE9 transgenic model (APP/PS1) to develop amyloid plaques. Mice were treated with NIR 20 times over a four-week period and NIR treatment (600-1000 nm) was associated with a reduction in the size and number of amyloid-β plaques in the neocortex and hippocampus. We now report a small pilot double blind, placebo-controlled trial (n=11) 6 active, 3 controls and 2 dropouts assessing the effect of 28 consecutive, sixminute transcranial sessions of near infrared (NIR) stimulation using 1060-1080 nm light emitting diodes. Subjects were independently diagnosed with dementia conducted in an outpatient behavioral healthcare clinic. IRB approval was obtained through the Quietmind Foundation's institutional review Board (IRB). Results showed changes in executive functioning; clock drawing, immediate recall, praxis memory, visual attention and task switching (Trails A&B) as well as a trend of improved EEG amplitude and connectivity measures. Neuroplasticity has also been reported with NIR light stimulation and mitochondrial enhancement.

Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.

Confianza de la comunidad

Cargando…

¿Cuánto confías en los hallazgos de este estudio?

0 · nada10 · totalmente

Comentarios

¿Algo está mal aquí?

Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.

Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.